医学部
Profile Information
- Affiliation
- School of Medicine Faculty of Medicine, Department of Advanced Endoscopy (formerly Department of Gastroenterology), Fujita Health University
- Degree
- 博士(医学)
- J-GLOBAL ID
- 200901011108502975
- researchmap Member ID
- 6000005568
患者さんの立場にたって、安全かつ最高の医療を提供できるよう努力します。
Research Interests
10Research Areas
1Committee Memberships
29-
Oct, 2026 - Present
-
Jul, 2023 - Present
Awards
5-
May, 2000
Papers
291-
Journal of Crohn's & colitis, 20(11), Nov 7, 2026BACKGROUND AND AIMS: Multiple advanced therapies are available for the treatment of Crohn's disease (CD). Treatment patterns in newly diagnosed patients and the factors associated with persistence remain unclear. We present interim results of the iCREST-CD registry describing treatment patterns and persistence with advanced therapies. METHODS: Patients aged ≥16 years with newly diagnosed CD and who had no prior exposure to advanced therapies were enrolled. Persistence of advanced therapies was estimated using Kaplan-Meier analyses, and associated factors were identified using multivariable Cox proportional hazards models. Persistence was also compared between patients who initiated therapy early or later after diagnosis. RESULTS: Of 672 patients (68.2% male; mean age 29.4 ± 13.1 years), 498 (74.1%) initiated advanced therapy: infliximab (IFX; 121), adalimumab (ADA; 244), ustekinumab (UST; 107), or vedolizumab (VDZ; 26). Advanced therapy was initiated within 1 year of diagnosis in 404 (60.1%). The 36-month treatment persistence rates for IFX, ADA, UST, and VDZ were 77.5%, 75.7%, 79.8%, and 49.0%, respectively. After propensity score adjustment using inverse probability of treatment weighting, the early initiation was associated with greater persistence than delayed initiation, although the difference did not reach statistical significance (hazard ratio, 0.61; 95% confidence interval, 0.35-1.09; P = .067). CONCLUSIONS: A high prevalence of early advanced therapy use and a high level of persistence with first-line advanced therapy were identified in this national cohort. Early initiation was associated with greater treatment persistence than delayed initiation, suggesting the potential clinical relevance of earlier advanced therapy use in routine practice. These findings require confirmation in other prospective studies aiming to evaluate early intervention strategies. REGISTRATION: The study was registered with the University Hospital Medical Information Network Clinical Trials Registry (umin.ac.jp/ctr Identifier: UMIN000032237) prior to initiation.
-
Gastrointestinal endoscopy, Sep 9, 2026
-
Journal of gastroenterology, 61(6) 732-740, Jun, 2026BACKGROUND: Primary small intestinal lymphoma (PSIL) is a rare disease, and its clinical characteristics and prognostic factors remain insufficiently defined because of limited large-scale data. METHODS: We conducted a nationwide multicenter retrospective study of 686 patients diagnosed with PSIL between January 2008 and December 2017 at 44 institutions in Japan. Clinical characteristics, histological subtypes, and overall survival were analyzed. RESULTS: B-cell lymphoma was the predominant immunophenotype (n = 623, 91%), whereas T-cell lymphoma was uncommon (n = 50, 7%). Diffuse large B-cell lymphoma (DLBCL) was the most frequent histological subtype (n = 330, 48%), followed by follicular lymphoma (FL) (n = 224, 33%). Compared with other B-cell lymphomas, FL was more common in women and more frequently involved the jejunum (P < 0.001). The 5-year overall survival rate was significantly higher in patients with B-cell lymphoma than in those with T-cell lymphoma (81% vs. 23%, P < 0.001). Multivariate Cox regression analysis identified age > 60 years and T-cell lymphoma as independent adverse prognostic factors, whereas FL was an independent predictor of favorable overall survival. CONCLUSIONS: This nationwide multicenter analysis delineates the clinicopathological features and survival outcomes of PSIL in Japan. FL represents the second most common subtype after DLBCL and is associated with a favorable prognosis among PSIL subtypes.
-
Gastrointestinal Endoscopy, 103(5) S-2512, May, 2026
Misc.
1339-
日本医事新報, (5313) 39-42, Feb, 2026
Books and Other Publications
51-
Springer, May, 2025 (ISBN: 9783031647185)
Presentations
456-
IDEN(International Digestive Endoscopy Network) 2026 Seoul, Jun 12, 2026 Invited
-
第111回日本消化器内視鏡学会総会, May 8, 2026
-
第112回日本消化器病学会総会, Apr 18, 2026
Teaching Experience
7Professional Memberships
12Research Projects
31-
Grants-in-Aid for Scientific Research, Japan Society for the Promotion of Science, Apr, 2022 - Mar, 2025
-
Grants-in-Aid for Scientific Research Grant-in-Aid for Scientific Research (C), Japan Society for the Promotion of Science, Apr, 2022 - Mar, 2025
-
Advanced medical care B, Ministry of Health, Labour and Welfare, Feb, 2021 - Jun, 2024
-
令和6年度 医療機器等研究成果展開事業(開発実践タイプ), 国立研究開発法人日本医療研究開発機構(AMED), Jun, 2024
-
令和3年度難治性疾患実用化研究事業, 国立研究開発法人日本医療研究開発機構(AMED), May, 2021 - Mar, 2024